Stereotactic Radiation Therapy in Treating Patients With Liver Metastases

• Toxicity profile [ Designated as safety issue: Yes ]
• Adverse events profile [ Designated as safety issue: Yes ]
• Quality of life as measured by the Brief Pain Inventory and Brief Fatigue Inventory [ Designated as safety issue: No ]
• Response profile [ Designated as safety issue: No ]
• Physical exam results [ Designated as safety issue: No ]

• Toxicity profile
• Adverse events profile
• Quality of life as measured by the Brief Pain Inventory and Brief Fatigue Inventory
• Response profile
• Physical exam results

RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiation therapy in treating patients with liver metastases.

OBJECTIVES:

• To identify the maximum tolerated dose of stereotactic radiation therapy in patients with hepatic metastases.
• To determine the toxicity and adverse events profile of this patient population.
• To examine patient response, treatment effect on blood chemistry, and hematology values and patient quality-of-life in this patient population.

OUTLINE: Patients are stratified according to stereotactic radiotherapy level (1 vs 2 vs 3) and the number of liver lesions present (1-2 vs 3-5 vs > 5).

Patients undergo percutaneous placement of metallic fiducial markers within the liver for stereotactic targeting and planning. Patients then undergo 1 fraction of stereotactic radiotherapy within 1 week of the marker placement.

Patients complete Brief Pain Inventory and Brief Fatigue Inventory questionnaires to assess quality of life at weeks 2, 4, 6, 8 and months 3, 6, and 9 after completion of study treatment.

After completion of study treatment, patients are followed for at least 8 weeks.

• Procedure: quality-of-life assessment
• Radiation: stereotactic body radiation therapy

DISEASE CHARACTERISTICS:

• Metastatic liver lesion ≤ 5 cm in dimension
• Willing and able to undergo percutaneous placement of localization seeds

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Life expectancy ≥ 12 weeks
• Platelet count ≥ 75,000/µL
• Hemoglobin ≥ 9 g/dL
• ANC ≥ 1,500/mL
• Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
• AST ≤ 3 x ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to complete questionnaires alone or with assistance
• No medical, social, or economic circumstance, that is likely to prevent adherence with the protocol

PRIOR CONCURRENT THERAPY:

• No prior radiation therapy to the liver
• No chemotherapy ≤ 4 weeks prior to registration
• Able to safely go without chemotherapy for 4 weeks after stereotactic radiotherapy (e.g., patients must not have or need chemotherapy in the 8 weeks [4 weeks prior to and 4 weeks after registration] surrounding stereotactic radiotherapy